Regeneron Pharmaceuticals has experienced a variably turbulent period. Investor panic rose with an increased fear concerning high-dose Eylea becoming less effective. However, third quarter results for 2024 were robust and surpassed anticipations, demonstrating strong revenue growth primarily driven by Eylea HD and Dupixent sales. The company's Q3 earnings snapshot reveals an EPS soar to $11.54. These factors make it an attractive investment opportunity. Despite such strengths, Regeneron Pharmaceuticals faced a severe setback following a court ruling in favor of
Amgen's Biosimilar of Eylea. Sharp concerns arose due to insider disposals of company stocks. Discouragingly, Frank R. Cruz's Law Offices are investigating Regeneron on behalf of investors, a phase that may impact its stock price adversely. For Regeneron's future prospects, the continued investment in oncology and collaboration with
Mammoth for gene editing therapies could serve as a growth engine. However, regulatory approval setbacks for its blood cancer therapy negatively impact the company's progress. As the company's intrinsic value is reportedly 81% greater than its share price, the market might undervalue REGN.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 25 Mar 2024 07:00:00 GMT to Fri, 01 Nov 2024 19:44:00 GMT -
Rating 0
- Innovation 2
- Information 7
- Rumor 3
